Involvement of single-nucleotide polymorphisms in predisposition to head and neck cancer in Saudi Arabia

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 2, 2012, Pages 95-101

  Al Hadyan, Khaled S ^a   Al Harbi, Najla M ^a   Al Qahtani, Sara S ^a   Alsbeih, Ghazi A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BIOLOGICAL MARKER; DNA; DNA LIGASE 4 C9T; KU80 PROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; XRCC1 PROTEIN; XRCC3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; SAUDI ARABIA; YOUNG ADULT;

EID: 84857540246     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0126     Document Type: Article

References (32)

1. Alsbeih G, Al-Harbi N, Al-Hadyan K, et al. (2010) Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res 173:505-511.
2. Authority NCR (2006) Cancer Incidence Report: Saudi Arabia, Ministry of Health, Saudi Cancer Registry
3. Bau DT, Fu YP, Chen ST, et al. (2004) Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 64:5013-5019.
4. Bettendorf O, Piffko J, Bankfalvi A (2004) Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 40:110-119.
5. Bond GL, Hu W, Bond EE, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602.
6. Brookes AJ (1999) The essence of SNPs. Gene 234:177-186.
7. Chiu CF, Wang CH, Wang CL, et al. (2008) A novel single nucleotide polymorphism in XRCC4 gene is associated with gastric cancer susceptibility in Taiwan. Ann Surg Oncol 15:514-518.
8. Chung CH, Gillison ML (2009) Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15:6758-6762.
9. Facher EA, Becich MJ, Deka A, Law JC (1997) Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 79:2424-2429.
10. Hashibe M, Brennan P, Benhamou S, et al. (2007) Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99:777-789.
11. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
12. Ho T, Wei Q, Sturgis EM (2007) Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 29:682-699.
13. Hsu CF, Tseng HC, Chiu CF, et al. (2009) Association between DNA double strand break gene Ku80 polymorphisms and oral cancer susceptibility. Oral Oncol 45:789-793.
14. Hu Z, Jin G, Wang L, et al. (2007) MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16:2717-2723.
15. Hu Z, Ma H, Lu D, et al. (2006) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 118:1275-1278.
16. Huang SP, Wu WJ, Chang WS, et al. (2004) p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2217-2224.
17. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303.
18. Li G, Zhai X, Zhang Z, et al. (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27:2028-2033.
19. Lukas J, Groshen S, Saffari B, et al. (1997) WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 150:167-175.
20. Ma H, Hu Z, Zhai X, et al. (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240:261-267.
21. Millikan RC, Heard K, Winkel S, et al. (2006) No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175-177.
22. Momand J, Zambetti GP, Olson DC, et al. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
23. Mousses S, Ozcelik H, Lee PD, et al. (1995) Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 4:1089-1092.
24. Oliner JD, Pietenpol JA, Thiagalingam S, et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
25. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
26. Phang BH, Linn YC, Li H, Sabapathy K (2008) MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 44:760-766.
27. Powell BL, Van Staveren IL, Roosken P, et al. (2002) Associations between common polymorphisms in TP53 and p21WAF1/ Cip1 and phenotypic features of breast cancer. Carcinogenesis 23:311-315.
28. Schmidt MK, Reincke S, Broeks A, et al. (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584-9590.
29. Shiohara M, el-Deiry W, Wada M, et al. (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784.
30. Siemiatycki J, Richardson L, Straif K, et al. (2004) Listing occupational carcinogens. Environ Health Perspect 112:1447-1459.
31. Yang M, Guo Y, Zhang X, et al. (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28:1996-2001.
32. Zhou G, Zhai Y, Cui Y, et al. (2007) MDM2 promoter SNP309 is associated with risk of occurrence and adVanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 13:2627-2633.